Compare HY & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HY | OVID |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 649.1M | 522.6M |
| IPO Year | 2012 | 2017 |
| Metric | HY | OVID |
|---|---|---|
| Price | $31.86 | $2.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.60 |
| AVG Volume (30 Days) | 84.1K | ★ 3.4M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.76% | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,769,300,000.00 | $7,252,000.00 |
| Revenue This Year | $1.37 | N/A |
| Revenue Next Year | $5.29 | $19.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $26.41 | $0.36 |
| 52 Week High | $44.55 | $3.11 |
| Indicator | HY | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 37.76 | 60.23 |
| Support Level | $29.88 | $2.23 |
| Resistance Level | $34.57 | $3.05 |
| Average True Range (ATR) | 1.78 | 0.19 |
| MACD | -0.55 | 0.04 |
| Stochastic Oscillator | 7.15 | 86.05 |
Hyster Yale Inc designs, engineers, manufactures, sells, and services a comprehensive line of lift trucks, attachments, aftermarket parts, and technology solutions marketed globally under the Hyster and Yale brand names. The company has four segments, which include three in the lift truck business as discussed below, as well as Bolzoni S.p.A. (Bolzoni). The majority of its revenue is generated from Lift Trucks. Geographically, it operates in America, EMEA, and JAPIC regions, of which maximum revenue is generated from its business in America, which includes lift truck operations in the U.S., Canada, Mexico, Brazil, and Latin America.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.